Over the past 12 months, 1 insider at TREACE MEDICAL CONCEPTS, INC. filed 2 open-market SEC Form 4 transactions on TMCI: 2 purchases worth $99K and 0 sales worth $0. Insiders have been net buyers over this period. The most recent filing was on Jun 11, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 11, 26 | John T. TreaceChief Executive Officer | BUY | 9.9K | $4.04 | $40K |
| Jun 10, 26 | John T. TreaceChief Executive Officer | BUY | 14.7K | $4.02 | $59K |
| Mar 17, 25 | Sean F. ScanlanChief Innovation Officer | SELL | 50.0K | $7.97 | $399K |
| Mar 4, 25 | John T. TreaceChief Executive Officer | BUY | 60.0K | $8.73 | $524K |
| Sep 16, 24 | John T. TreaceChief Executive Officer | BUY | 50.0K | $5.31 | $266K |
| Aug 15, 24 | James T TreaceDirector | BUY | 84.0K | $5.96 | $501K |
| Aug 14, 24 | John T. TreaceChief Executive Officer | BUY | 85.0K | $6.00 | $510K |
| Jun 11, 24 | John T. TreaceChief Executive Officer | BUY | 45.0K | $5.88 | $265K |
| May 31, 24 | James T TreaceDirector | BUY | 25.0K | $6.05 | $151K |
| May 29, 24 | James T TreaceDirector | BUY | 25.0K | $5.20 | $130K |
| May 28, 24 | James T TreaceDirector | BUY | 50.0K | $5.07 | $254K |
| May 24, 24 | Richard W MottDirector | BUY | 18.0K | $5.19 | $93K |
| May 22, 24 | Richard W MottDirector | BUY | 12.1K | $4.99 | $60K |
| May 17, 24 | John T. TreaceChief Executive Officer | BUY | 100.0K | $5.56 | $556K |
| May 14, 24 | Jane E KiernanDirector | BUY | 19.4K | $5.17 | $100K |
| May 14, 24 | John T. TreaceChief Executive Officer | BUY | 150.0K | $5.12 | $768K |
| May 13, 24 | Richard W MottDirector | BUY | 36.8K | $4.38 | $161K |
| May 13, 24 | James T TreaceDirector | BUY | 145.0K | $4.54 | $658K |
| May 13, 24 | John T. TreaceChief Executive Officer | BUY | 150.0K | $4.56 | $684K |
| May 10, 24 | John K BakewellDirector | BUY | 130.0K | $4.57 | $594K |
| May 10, 24 | Deepti JainDirector | BUY | 25.0K | $4.50 | $113K |
| May 10, 24 | Richard W MottDirector | BUY | 83.2K | $4.57 | $380K |
| May 10, 24 | James T TreaceDirector | BUY | 83.0K | $4.53 | $376K |
| May 10, 24 | John T. TreaceChief Executive Officer | BUY | 150.0K | $4.58 | $687K |
| Jun 5, 23 | F Barry BaysOther | SELL | 1.04M | $26.51 | $27.6M |
| Jun 2, 23 | F Barry BaysOther | SELL | 48.5K | $26.51 | $1.3M |
| May 16, 23 | Sean F. ScanlanChief Innovation Officer | SELL | 25.0K | $25.44 | $636K |
| May 1, 23 | James T TreaceDirector | SELL | 7.6K | $25.91 | $191K |
| Apr 28, 23 | James T TreaceDirector | SELL | 40.0K | $25.01 | $1.0M |
| Apr 27, 23 | F Barry BaysDirector | SELL | 11.6K | $25.35 | $294K |
| Apr 26, 23 | F Barry BaysDirector | SELL | 16.2K | $25.55 | $414K |
| Apr 12, 23 | F Barry BaysDirector | SELL | 36.4K | $26.12 | $950K |
| Apr 11, 23 | F Barry BaysDirector | SELL | 44.8K | $27.28 | $1.2M |
| Apr 6, 23 | Richard W MottDirector | SELL | 4.0K | $26.00 | $105K |
| Apr 4, 23 | Richard W MottDirector | SELL | 15.8K | $26.00 | $410K |
| Apr 3, 23 | Richard W MottDirector | SELL | 201 | $26.00 | $5K |
| Mar 31, 23 | Richard W MottDirector | SELL | 95.0K | $25.36 | $2.4M |
| Mar 30, 23 | Richard W MottDirector | SELL | 38.5K | $26.00 | $1.0M |
| Mar 30, 23 | James T TreaceDirector | SELL | 50.0K | $25.86 | $1.3M |
| Mar 29, 23 | F Barry BaysDirector | SELL | 32.5K | $25.28 | $821K |
| Mar 28, 23 | F Barry BaysDirector | SELL | 26.2K | $25.02 | $657K |
| Mar 15, 23 | Daniel E. OwensOther | SELL | 6.3K | $22.87 | $143K |
| Mar 15, 23 | Thomas E TimbieDirector | SELL | 50.0K | $23.03 | $1.2M |
| Mar 14, 23 | F Barry BaysDirector | SELL | 9.4K | $23.25 | $219K |
| Mar 13, 23 | F Barry BaysDirector | SELL | 8.3K | $24.73 | $200K |
| Mar 9, 23 | Aaron BeruttiSr. VP, Sales | SELL | 733 | $24.41 | $18K |
| Mar 9, 23 | Scot Michael Elder"*See ""Remarks""" | SELL | 177 | $24.41 | $4K |
| Mar 9, 23 | Mark HairChief Financial Officer | SELL | 1.0K | $24.41 | $25K |
| Mar 9, 23 | Daniel E. OwensOther | SELL | 411 | $24.41 | $10K |
| Mar 9, 23 | Sean F. ScanlanChief Innovation Officer | SELL | 505 | $24.41 | $12K |
Over the past 12 months, insiders at TREACE MEDICAL CONCEPTS, INC. filed 2 open-market purchases worth $99K and 0 sales worth $0 on TMCI, which makes them net buyers over the period. The most recent Form 4 was filed on Jun 11, 26.
The largest recent open-market TMCI insider purchase in our data was $768K by John T. Treace, Chief Executive Officer, filed on May 14, 24.
1 different insider at TREACE MEDICAL CONCEPTS, INC. filed open-market SEC Form 4 transactions on TMCI over the last 12 months.
InsiderTape plots every TMCI insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every TREACE MEDICAL CONCEPTS, INC. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →